Here at FierceDrugDelivery, we write often about innovations in nanotechnology as it becomes more and more important in the delivery field. These advances are mostly in the very early stages, but they're still promising as the delivery field moves even further into the nanoscale.
Sanofi is doubling down on its RNAi development deal with Alnylam. The pharma giant says it will pay a hefty premium to buy up a 12% stake in the biotech, investing $700 million and greatly expanding its rights to Alnylam's lead drug along with a portfolio of current and prospective therapies.
Gene-silencing expert Alnylam is $7 million richer thanks to some positive mid-stage results for its Genzyme-licensed RNA-interference candidate, and the Cambridge, MA, company is looking to be the first to market with the difficult-to-deliver class of treatments.
Alnylam, a specialist in RNAi drug delivery, welcomed positive results in an early-stage trial of its treatment designed to silence the gene that causes a rare, deadly form of the disease amyloidosis. The data establish human translation for Alnylam's conjugate delivery platform, the company says.
Cambridge, MA-based Alnylam Pharmaceuticals says it garnered positive interim data from a Phase I study of ALN-TTRsc, an RNAi therapy targeting the transthyretin gene for the treatment of TTR-mediated amyloidosis.
Regulus Therapeutics, a biotech using microRNA as a target for drug delivery, raised nearly $49 million through a public offering completed Tuesday, up from an anticipated $43 million.
The top-line results from a Phase I study show that its therapy ALN-TTRsc reduced levels of Transthyretin (TTR)-mediated amyloidosis protein by more than 80%, setting the stage for a mid-stage study planned for late this year in patients with a genetic heart disease called familial amyloidotic cardiomyopathy (FAC).
Alnylam chugged along this week in its efforts to advance its line of RNAi drugs to the market, notching positive results for two of its candidates in Phase II and preclinical trials.
Alnylam Pharmaceuticals heralded positive preclinical data for its RNAi drug that targets a specific protein to treat a range of life-threatening diseases.
Alnylam Pharmaceuticals, a leader in the research and development of RNAi drug delivery, arrived at a successful proof-of-concept result for its gene-silencing treatment to temper a rare and deadly autosomal disease.